Grace Therapeutics, Inc. Amortization of Debt Issuance Costs
Grace Therapeutics, Inc. (GRCE) reported Amortization of Debt Issuance Costs of $0 for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2021-08-12
- Grace Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2020-06-30 was $121.00K.
- Grace Therapeutics, Inc. amortization of debt issuance costs for fiscal 2021 was $264.00K, a 473.91% increase from fiscal 2020.
- Grace Therapeutics, Inc. amortization of debt issuance costs for fiscal 2020 was $46.00K, a 90.93% decline from fiscal 2019.
- Grace Therapeutics, Inc. amortization of debt issuance costs for fiscal 2019 was $507.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $264.00K 10-K · filed 2021-06-22 | |
| 2020-06-30 | $121.00K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $46.00K 10-K · filed 2021-06-22 | |
| 2019-03-31 | $507.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |